Alnylam Q2 2026 Product Net Revenue $1.172 Billion, Shares Slump 28% on Guidance Cut
Alnylam reported Q2 2026 product net revenue of $1.172 billion, up 74% year-on-year. Amvuttra sales exceeded $1 billion for the first time, reaching $1.012 billion, up 106%. However, the company trimmed its full-year TTR pipeline sales guidance to $4.2-4.5 billion from $4.4-4.7 billion, sending shares down 28% to a market cap below $30 billion. The company highlighted slowing growth in second-line Amvuttra use in the US, with 80% of new starts being first-line.
- Effective
- -9
- Intensity
- 45
- Confidence
- 75%
- Horizon
- Short term